Hypofractionated Radiation Shortens Prostate Cancer Treatment with Little Quality of Life Impact

Hypofractionated Radiation Shortens Prostate Cancer Treatment with Little Quality of Life Impact
Treating early stage prostate cancer with hypofractionated radiation therapy (HRT) results in fairly similar health-related quality of life outcomes as conventional radiation therapy (CRT), but reduces treatment time by up to one-third, according to a study by Deborah Watkins Bruner, PhD, and colleagues at the Winship Cancer Institute of Emory University. The study, “NRG Oncology/RTOG 0415, Phase 3 Noninferiority Study Comparing 2 Fractionation Schedules in Patients With Low-Risk Prostate Cancer: Prostate-Specific Quality of Life Results,” was presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO), September 25-28, in Boston. "Studies have suggested that higher amounts of radiation over shorter periods of time might be more effective in destroying cancer cells, but the concern has been that stronger doses might also cause quality of life issues such as more diarrhea or decrease in sexual function," Bruner said in a news release. To address the concern, the researchers looked at the NRG Oncology/RTOG 0415 randomized Phase 3 trial (NCT00331773) that evaluated the effectiveness of hypofractionated RT versus conventional RT. In the study, patients with stage 2 prostate cancer, median age 67 years, were randomized to receive either CRT (73.8 Gy in 41 daily treatments delivered over 8.2 weeks) or HRT (70 Gy in 28 daily treatments delivered over 5.6 weeks). Although the study's efficacy results had already been reported, nothing was known regarding the study patient
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *